Human immunodeficiency virus type 1: Resistance to nucleoside analogues and replicative capacity in primary human macrophages

Journal of Virology

Volumn 81, Issue 9, 2007, Pages 4540-4550

  Perez Bercoff, Danielle ^a,b   Wurtzer, Sébastien ^a,b   Compain, Séverine ^c   Benech, Henri ^c   Clavel, François ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Institut National de la Recherche Agronomique   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYNUCLEOSIDE TRIPHOSPHATE; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE TRIPHOSPHATE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; HELA CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS REPLICATION;

ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; CELL LINE; DNA PRIMERS; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MACROPHAGES; MUTATION; NUCLEOSIDES; PLASMIDS; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34247583931     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01620-06     Document Type: Article

References (67)

1. Aquaro, S., P. Bagnarelli, T. Guenci, A. De Luca, M. Clementi, E. Balestra, R. Calio, and C. F. Perno. 2002. Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J. Med. Virol. 68:479-488.
2. Aquaro, S., E. Balestra, S. Panti, A. Cenci, F. Serra, M. Francesconi, D. Abdelahad, R. Calio, and C. F. Perno. 1998. Correlation between HIV-inhibiting drug activity in human macrophages and clinical outcome. Clin. Ter. 149:37-41. (In Italian.)
3. Aquaro, S., R. Calio, J. Balzarini, M. C. Bellocchi, E. Garaci, and C. F. Perno. 2002. Macrophages and HIV infection: therapeutic approaches toward this strategic virus reservoir. Antivir. Res. 55:209-225.
4. Aquaro, S., C. F. Perno, E. Balestra, J. Balzarini, A. Cenci, M. Francesconi, S. Panti, F. Serra, N. Villani, and R. Calio. 1997. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J. Leukoc. Biol. 62:138-143.
5. Aquaro, S., V. Svicher, F. Ceccherini-Silberstein, A. Cenci, F. Marcuccilli, S. Giannella, L. Mareen, R. Calio, J. Balzarini, and C. F. Perno. 2005. Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages. J. Antimicrob. Chemother. 55:872-878.
6. Arion, D., G. Borkow, Z. Gu, M. A. Wainberg, and M. A. Parniak. 1996. The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase. J. Biol. Chem. 271:19860-19864.
7. Arner, E. S., A. Valentin, and S. Eriksson. 1992. Thymidine and 3′-azido-3′-deoxythymidine metabolism in human peripheral blood lymphocytes and monocyte-derived macrophages. A study of both anabolic and catabolic pathways. J. Biol. Chem. 267:10968-10975.
8. Arts, E. J., J. P. Marois, Z. Gu, S. F. Le Grice, and M. A. Wainberg. 1996. Effects of 3′-deoxynucleoside 5′-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA. J. Virol. 70:712-720.
9. Back, N. K., and B. Berkhout. 1997. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 41:2484-2491.
10. Back, N. K., M. Nijhuis, W. Keulen, C. A. Boucher, B. O. Oude Essink, A. B. van Kuilenburg, A. H. van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-rcsistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
11. Balzarini, J., R. Pauwels, M. Baba, P. Herdewijn, E. de Clercq, S. Broder, and D. G. Johns. 1988. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′,3′- dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Bioehem. Pharmacol. 37:897-903.
12. Becher, F., A. Pruvost, C. Goujard, C. Guerreiro, J. F. Delfraissy, J. Grassi, and H. Benech. 2002. Improved method for the simultaneous determination of d4T, 3TC and ddI intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 16:555-565.
13. Becher, F., D. Schlemmer, A. Pruvost, M. C. Nevers, C. Goujard, S. Jorajuria, C. Guerreiro, T. Brossette, L. Lebeau, C. Creminon, J. Grassi, and H. Benech. 2002. Development of a direct assay for measuring intracellular AZT triphosphate in humans peripheral blood mononuclear cells. Anal. Chem. 74:4220-4227.
14. Bouchonnet, F., E. Dam, F. Mammano, V. de Soultrait, G. Hennere, H. Benech, F. Clavel, and A. J. Hance. 2005. Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues. J. Virol. 79:812-822.
15. Boyer, P. L., and S. H. Hughes. 1995. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39:1624-1628.
16. Caliendo, A. M., A. Savara, D. An, K. DeVore, J. C. Kaplan, and R. T. D'Aquila. 1996. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J. Virol. 70:2146-2153.
17. Castagna, A., A. Danise, S. Menzo, L. Galli, N. Gianotti, E. Carini, E. Boeri, A. Galli, M. Cernuschi, H. Hasson, M. Clementi, and A. Lazzarin. 2006. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 20:795-803.
18. Charneau, P., G. Mirambeau, P. Roux, S. Paulous, H. Buc, and F. Clavel. 1994. HIV-1 reverse transcription: a termination step at the center of the genome. J. Mol. Biol. 241:651-662.
19. Clavel, F., and A. J. Hance. 2004. HIV drug resistance. N. Engl. J. Med. 350:1023-1035.
20. Coakley, E. P., J. M. Gillis, and S. M. Hammer. 2000. Phenotypic and genotypie resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 14:F9-F15.
21. Deeks, S. G., R. Hoh, T. B. Neilands, T. Liegler, F. Aweeka, C. J. Petropoulos, R. M. Grant, and J. N. Martin. 2005. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J. Infect. Dis. 192:1537-1544.
22. Deval, J., K. L. White, M. D. Miller, N. T. Parkin, J. Courcambeck, P. Halfen, B. Selmi, J. Boretto, and B. Canard. 2004. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem. 279:509-516.
23. Diamond, T. L., M. Roshal, V. K. Jamburuthugoda, H. M. Reynolds, A. R. Merriam, K. Y. Lee, M. Balakrishnan, R. A. Bambara, V. Planelles, S. Dewhurst, and B. Kim. 2004. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J. Biol. Chem. 279:51545- 51553.
24. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-didcoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
25. Gao, W. Y., T. Shirasaka, D. G. Johns, S. Broder, and H. Mitsuya. 1993. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Investig. 91:2326-2333.
26. Garach E., M. C. Caroleo, L. Aloe, S. Aquaro, M. Piacentini, N. Costa, A. Amendola, A. Micera, R. Calio, C. F. Perno, and R. Levi-Montalcini. 1999. Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV. Proc. Natl. Acad. Sci. USA 96:14013-14018.
27. Geleziunas, R., A. E., F. Boulerice, H. Goldman, and M. A. Wainberg. 1993. Effect of 3′-azido-3′-deoxythymidine on human immunodeficiency virus type 1replication in human fetal brain macrophages. Antimicrob. Agents Chemother. 37:1305-1312.
28. Gendelman, H. E., J. M. Orenstein, M. A. Martin, C. Ferrua, R. Mitra, T. Phipps, L. A. Wahl, H. C. Lane, A. S. Fauci, D. S. Burke, et al. 1988. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167:1428-1441.
29. Hennere, G., F. Becher, A. Pruvost, C. Goujard, J. Grassi, and H. Benech. 2003. Liquid chromatography-tandem mass spectrometry assays for intracellular deoxyribonucleotide triphosphate competitors of nucleoside antiretrovirals. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 789:273-281.
30. Hertogs, K., M. P. de Bethune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
31. Higashikawa, F., and L. Chang. 2001. Kinetic analyses of stability of simple and complex retroviral vectors. Virology 280:124-131.
32. Koenig, S., H. E. Gendelman, J. M. Orenstein, M. C. Dal Canto, G. H. Pezeshkpour, M. Yungbluth, F. Janotta, A. Aksamit, M. A. Martin, and A. S. Fauci. 1986. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233:1089-1093.
33. Lambotte, O., Y. Taoufik, M. G. de Goer, C. Wallon, C. Goujard, and J. F. Delfraissy. 2000. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 23:114-119.
34. Mammano, F., V. Trouplin, V. Zennou, and F. Clavel. 2000. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 74:8524-8531.
35. Margot, N. A., E. Isaacson, I. McGowan, A. K. Cheng, R. T. Schooley, and M. D. Miller. 2002. Genotypie and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tcnofovir DF. AIDS 16:1227-1235.
36. Masquelier, B., E. Race, C. Tamalet, D. Descamps, J. Izopet, C. Buffet-Janvresse, A. Ruffault, A. S. Mohammed, J. Cottalorda, A. Schmuck, V. Calvez, E. Dam, H. Fleury, and F. Brun-Vezinet. 2001. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. Antimicrob. Agents Chemother. 45:1836-1842.
37. Maxeiner, H. G., W. Keulen, R. Schuurman, M. Bijen, L. de Graaf, A. van Wijk, N. Back, M. W. Kline, C. A. Boucher, and M. Nijhuis. 2002. Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients. J. Infect. Dis. 185:1070-1076.
38. McElrath, M. J., J. E. Pruett, and Z. A. Cohn. 1989. Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. Proc. Natl. Acad. Sci. USA 86:675-679.
39. Meltzer, M. S., M. Nakamura, B. D. Hansen, J. A. Turpin, D. C. Kalter, and H. E. Gendelman. 1990. Macrophages as susceptible targets for HIV infection, persistent viral reservoirs in tissue, and key immunoregulatory cells that control levels of virus replication and extent of disease. AIDS Res. Hum. Retrovir. 6:967-971.
40. Meyer, P. R., S. E. Matsuura, A. M. Mian, A. G. So, and W. A. Scott. 1999. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4:35-43.
41. Meyer, P. R., S. E. Matsuura, R. F. Schinazi, A. G. So, and W. A. Scott. 2000. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob. Agents Chemother. 44:3465-3472.
42. Meyer, P. R., S. E. Matsuura, A. G. So, and W. A. Scott. 1998. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. USA 95:13471- 13476.
43. Meyer, P. R., S. E. Matsuura, A. A. Tolun, I. Pfeifer, A. G. So, J. W. Mellors, and W. A. Scott. 2002. Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 46:1540-1545.
44. Miller, M. D. 2004. K65R, TAMs, and tenofovir. AIDS Rev. 6:22-33.
45. Miller, M. D., K. E. Anton, A. S. Mulato, P. D. Lamy, and J. M. Cherrington. 1999. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J. Infect. Dis. 179:92-100.
46. Miller, V., and B. A. Larder. 2001. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir. Ther. 6(Suppl. 3):25-44.
47. Miller, V., T. Stark, A. E. Loeliger, and J. M. Lange. 2002. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med. 3:135-145.
48. Naeger, L. K., N. A. Margot, and M. D. Miller. 2002. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 46:2179-2184.
49. Orenstein, J. M., C. Fox, and S. M. Wahl. 1997. Macrophages as a source of HIV during opportunistic infections. Science 276:1857-1861.
50. Orenstein, J. M., M. S. Meltzer, T. Phipps, and H. E. Gendelman. 1988. Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study. J. Virol. 62:2578-2586.
51. Pellegrin, I., J. Izopet, J. Reynes, M. Denavrolles, B. Montes, J. L. Pellegrin, P. Massip, J. Puel, H. Fleury, and M. Segondy. 1999. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group. AIDS 13:1705-1709.
52. Perno, C. F., E. Balestra, M. Francesconi, D. Abdelahad, R. Calio, J. Balzarini, and S. Aquaro. 2004. Antiviral profile of HIV inhibitors in macrophages: implications for therapy. Curr. Top. Med. Chem. 4:1009-1015.
53. Perno, C. F., R. Yarchoan, J. Balzarini, A. Bergamini, G. Milanese, R. Pauwels, E. De Clercq, G. Rocchi, and R. Calio. 1992. Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages. Antivir. Res. 17:289-304.
54. Perno, C. F., R. Yarchoan, D. A. Cooney, N. R. Hartman, S. Gartner, M. Popovic, Z. Hao, T. L. Gerrard, Y. A. Wilson, D. G. Johns, et al. 1988. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J. Exp. Med. 168:1111-1125.
55. Petrella, M., M. Oliveira, D. Moisi, M. Detorio, B. G. Brenner, and M. A. Wainberg. 2004. Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrob. Agents Chemother. 48:4189-4194.
56. Petrella, M., and M. A. Wainberg. 2002. Might the M184V substitution in HIV-1 RT confer clinical benefit? AIDS Rev. 4:224-232.
57. Picard, V., E. Angelini, A. Maillard, E. Race, F. Clavel, G. Chene, F. Ferchal, and J. M. Molina. 2001. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J. Infect. Dis. 184:781-784.
58. Quan, Y., B. G. Brenner, M. Oliveira, and M. A. Wainberg. 2003. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrob. Agents Chemother. 47:747-754.
59. Quan, Y., Z. Gu, X. Li, Z. Li, C. D. Morrow, and M. A. Wainberg. 1996. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. J. Virol. 70:5642-5645.
60. Roy, B., C. Beuneu, P. Roux, H. Buc, G. Lemaire, and M. Lepoivre. 1999. Simultaneous determination of pyrimidine or purine deoxyribonucleoside triphosphates using a polymerase assay. Anal. Biochem. 269:403-409.
61. Sarafianos, S. G., K. Das, A. D. Clark, Jr., J. Ding, P. L. Boyer, S. H. Hughes, and E. Arnold. 1999. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl. Acad. Sci. USA 96:10027-10032.
62. Sharkey, M. E., I. Teo, T. Greenough, N. Sharova, K. Luzuriaga, J. L. Sullivan, R. P. Bucy, L. G. Kostrikis, A. Haase, C. Veryard, R. E. Davaro, S. H. Cheeseman, J. S. Daly, C. Bova, R. T. Ellison III, B. Mady, K. K. Lai, G. Moyle, M. Nelson, B. Gazzard, S. Shaunak, and M. Stevenson. 2000. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 6:76-81.
63. Sharma, P. L., and C. S. Crumpacker. 1997. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J. Virol. 71:8846-8851.
64. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
65. Traut, T. W. 1994. Physiological concentrations of purines and pyrimidines. Mol. Cell Biochem. 140:1-22.
66. Wainberg, M. A. 2004. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev. Anti-Infect. Ther. 2:147-151.
67. White, K. L., N. A. Margot, T. Wrin, C. J. Petropoulos, M. D. Miller, and L. K. Naeger. 2002. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 46:3437-3446.